Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$2.38 +8.7%	$1.48	$1.05 ▼ $8.79	$161.27M	-0.11	348,848 shs	799,687 shs
CMPX Compass Therapeutics	$3.02 +7.9%	$2.83	$1.19 ▼ $4.08	$417.61M	1.49	1.42 million shs	1.45 million shs
KMDA Kamada	$7.18 +1.8%	$7.47	$5.17 ▼ $9.15	$412.92M	0.93	131,527 shs	21,642 shs
PRTA Prothena	$8.77 +2.5%	$6.76	$4.32 ▼ $22.83	$472.09M	-0.03	1.06 million shs	1.24 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-2.67%	+27.33%	+55.32%	+85.59%	+218,999,900.00%
CMPX Compass Therapeutics	+0.72%	-5.08%	-8.79%	+33.97%	+135.29%
KMDA Kamada	+1.15%	-3.42%	-7.72%	+6.33%	+27.03%
PRTA Prothena	+0.47%	+6.20%	+31.09%	+30.09%	-61.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLYM Climb Bio	3.5946 of 5 stars	3.7	0.0	3.7	2.5	1.3
CMPX Compass Therapeutics	2.7504 of 5 stars	3.6	1.0	2.0	5.0	0.0
KMDA Kamada	4.6659 of 5 stars	3.3	5.0	3.3	1.7	4.4
PRTA Prothena	3.3009 of 5 stars	4.2	4.0	1.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.33	Buy	$9.00	278.15% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	326.78% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	81.06% Upside
PRTA Prothena	2.33	Hold	$30.25	244.93% Upside

Current Analyst Ratings Breakdown

Latest CLYM, PRTA, CMPX, and KMDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	CLYM Climb Bio	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/15/2025	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$9.00
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
8/5/2025	PRTA Prothena	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$18.00 ➝ $10.00
8/5/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/5/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$2.74 per share	N/A
CMPX Compass Therapeutics	$850K	491.30	N/A	N/A	$0.67 per share	4.51
KMDA Kamada	$160.95M	2.57	$0.51 per share	14.18	$4.52 per share	1.59
PRTA Prothena	$135.16M	3.49	N/A	N/A	$6.03 per share	1.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$73.90M	-$0.70	N/A	N/A	N/A	N/A	-23.10%	-22.47%	N/A
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	N/A
KMDA Kamada	$14.46M	$0.34	21.12	22.44	0.74	11.22%	7.41%	5.18%	N/A
PRTA Prothena	-$122.31M	-$5.64	N/A	N/A	N/A	-2,929.30%	-62.17%	-54.43%	N/A

Latest CLYM, PRTA, CMPX, and KMDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	KMDA Kamada	$0.09	$0.13	+$0.04	$0.13	$158.59 million	$44.75 million
8/12/2025	Q2 2025	CLYM Climb Bio	-$0.19	-$0.13	+$0.06	-$0.13	N/A	N/A
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/4/2025	Q2 2025	PRTA Prothena	-$1.11	-$1.86	-$0.75	-$2.34	$5.36 million	$4.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	14.08	14.08
CMPX Compass Therapeutics	N/A	7.66	7.66
KMDA Kamada	N/A	4.00	2.21
PRTA Prothena	N/A	5.68	5.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
CMPX Compass Therapeutics	68.43%
KMDA Kamada	20.38%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	0.80%
CMPX Compass Therapeutics	29.80%
KMDA Kamada	36.10%
PRTA Prothena	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	67.76 million	67.22 million	N/A
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable

CLYM, PRTA, CMPX, and KMDA Headlines

Recent News About These Companies

Analysts Set Prothena Corporation plc (NASDAQ:PRTA) Price Target at $30.25

August 17, 2025 | americanbankingnews.com

Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Hold" from Analysts

August 15, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?

August 14, 2025 | marketbeat.com

Citizens JMP Remains a Buy on Prothena (PRTA)

August 9, 2025 | theglobeandmail.com

FY2026 EPS Estimates for Prothena Lifted by Chardan Capital

August 9, 2025 | marketbeat.com

Cantor Fitzgerald Increases Earnings Estimates for Prothena

August 8, 2025 | marketbeat.com

FY2025 EPS Estimates for Prothena Reduced by HC Wainwright

August 8, 2025 | marketbeat.com

Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful

August 7, 2025 | msn.com

Prothena (NASDAQ:PRTA) Price Target Cut to $10.00 by Analysts at Royal Bank Of Canada

August 6, 2025 | marketbeat.com

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

August 6, 2025 | businesswire.com

Prothena's (PRTA) Buy Rating Reiterated at HC Wainwright

August 6, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Given "Buy" Rating at Chardan Capital

August 6, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Announces Earnings Results, Misses Expectations By $0.80 EPS

August 5, 2025 | marketbeat.com

9 Analysts Assess Prothena Corp: What You Need To Know

August 5, 2025 | benzinga.com

Prothena Reports Q2 2025 Financial Results and Pipeline Progress

August 4, 2025 | tipranks.com

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2025 | zacks.com

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

August 4, 2025 | businesswire.com

Prothena Corporation plc (NASDAQ:PRTA) Shares Purchased by DCF Advisers LLC

August 4, 2025 | marketbeat.com

Federated Hermes Inc. Sells 199,922 Shares of Prothena Corporation plc (NASDAQ:PRTA)

August 3, 2025 | marketbeat.com

A Glimpse of Prothena Corp's Earnings Potential

August 2, 2025 | benzinga.com

Prothena Secures Leadership with New Executive Agreements

July 31, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLYM, PRTA, CMPX, and KMDA Company Descriptions

Climb Bio NASDAQ:CLYM

$2.38 +0.19 (+8.68%)

As of 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Compass Therapeutics NASDAQ:CMPX

$3.02 +0.22 (+7.86%)

Closing price 04:00 PM Eastern

Extended Trading

$2.96 -0.06 (-2.12%)

As of 05:01 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Kamada NASDAQ:KMDA

$7.18 +0.13 (+1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$7.16 -0.02 (-0.28%)

As of 04:10 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Prothena NASDAQ:PRTA

$8.77 +0.21 (+2.45%)

Closing price 04:00 PM Eastern

Extended Trading

$8.72 -0.04 (-0.51%)

As of 05:25 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time